Want to see LQDA full AI Analyst Report?
LQDA Stock Chart & Stats
$39.47
<$0.01(<0.01%)
At close: 4:00 PM EST
$39.47
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$14.04 - $82.96
Previous CloseN/A
Volume97.81K
Average Volume (3M)2.32M
Market Cap
$6.80B
Enterprise Value$3.78K
Total Cash (Recent Filing)$222.79M
Total Debt (Recent Filing)$184.82M
Price to Earnings (P/E)325.2
Beta1.62
Next Earnings
Aug 06, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding88,928,100
10 Day Avg. Volume1,270,115
30 Day Avg. Volume2,317,711
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$75.14Price Target Upside90.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)3.3
Revenue Forecast (FY)$721.88M
Bulls Say, Bears Say
Bulls Say
Commercial Ramp & Market AdoptionRapid, reproducible commercial adoption of YUTREPIA demonstrates durable demand and distribution execution: strong sequential sales growth and expanding prescriber depth (≈980 prescribers, more physicians with ≥5 patients) indicate recurring revenue potential and a scalable sales model to support multi-year growth.
Profitability & Cash GenerationThe shift to sustained positive operating cash flow and free cash flow, plus a sizeable cash balance, materially improves financial flexibility. This self-funded cash generation supports ongoing manufacturing expansion and clinical programs without reliance on near-term external financing, reducing dilution risk.
Proprietary Technology & Pipeline ProgressOwning PRINT particle-engineering technology plus advancing differentiated assets (L606 pivotal study, ASCENT transitions) provides structural R&D advantages. Coupled with operating cash funding, this strengthens long-term product development optionality and potential lifecycle expansion of the inhaled prostacyclin franchise.
Bears Say
Patent Litigation RiskOngoing patent disputes create durable legal overhang: adverse rulings or injunctions could restrict exclusivity, lead to royalties or limit market access. The uncertainty complicates long-term revenue visibility and could force strategic or commercial changes that materially affect product economics.
Material Leverage Relative To EquityAlthough leverage has improved, the company still carries sizeable debt versus equity which constrains financial flexibility. Interest and amortization obligations can compete with R&D and commercial reinvestment, raising the bar for consistent cash generation to maintain strategic optionality.
Dependence On Sustained Adoption To Achieve TargetsFuture revenue materially depends on continued prescriber conversion, patient persistence, and successful transitions from competing therapies. Structural barriers like underdiagnosis and community adoption gaps mean any slowdown in uptake or reimbursement shifts could materially delay or reduce projected long-term revenue.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies’s price range in the past 12 months?
Liquidia Technologies lowest stock price was $14.04 and its highest was $82.96 in the past 12 months.
What is Liquidia Technologies’s market cap?
Liquidia Technologies’s market cap is $6.80B.
When is Liquidia Technologies’s upcoming earnings report date?
Liquidia Technologies’s upcoming earnings report date is Aug 06, 2026 which is in 20 days.
How were Liquidia Technologies’s earnings last quarter?
Liquidia Technologies released its earnings results on May 11, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11.
Is Liquidia Technologies overvalued?
According to Wall Street analysts Liquidia Technologies’s price is currently Undervalued.
Does Liquidia Technologies pay dividends?
Liquidia Technologies does not currently pay dividends.
What is Liquidia Technologies’s EPS estimate?
Liquidia Technologies’s EPS estimate is 0.76.
How many shares outstanding does Liquidia Technologies have?
Liquidia Technologies has 88,928,100 shares outstanding.
What happened to Liquidia Technologies’s price movement after its last earnings report?
Liquidia Technologies reported an EPS of $0.52 in its last earnings report, beating expectations of $0.41. Following the earnings report the stock price went up 25.603%.
Which hedge fund is a major shareholder of Liquidia Technologies?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.14 (90.38% Upside)
$75.14 (90.38% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 25.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $108.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
435.83%
12-Months-Change
Fundamentals
Return on Equity
46.82%
Trailing 12-Months
Asset Growth
76.55%
Trailing 12-Months
Company Description
Liquidia Technologies
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
LQDA Stock 12 Month Forecast
Average Price Target
$75.14
▲(90.38% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
30.74% Insiders
8.46% Mutual Funds
0.29% Other Institutional Investors
43.16% Public Companies and Individual Investors